Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers

Patent metadata

Field	Value
Publication number	US-10709736-B2
Application number	US-201916703061-A
Country	US
Kind code	B2
Filing date	Dec 4, 2019
Priority date	Feb 21, 2018
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 6,
wherein said cancer is selected from AML (acute myeloid leukemia), BRCA (breast cancer), CCC (cholangiocellular carcinoma), CRC (colorectal cancer), GBM (glioblastoma), GC (gastric cancer), HCC (hepatocellular carcinoma), HNSCC (head and neck squamous cell carcinoma), MEL (melanoma), NHL (non-Hodgkin lymphoma), NSCLC (non-small cell lung cancer), OC (ovarian cancer), OSCAR (esophageal cancer), RCC (renal cell carcinoma), SCLC (small cell lung cancer), UBC (urinary bladder carcinoma), and UEC (uterine endometrial cancer).

2. The method of claim 1 , wherein the T cells are autologous to the patient.

3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.

4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.

5. The method of claim 1 , wherein the activated T cells are expanded in vitro.

6. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.

7. The method of claim 6 , wherein the composition further comprises an adjuvant.

8. The method of claim 7 , wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

9. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

10. The method of claim 9 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.

11. The method of claim 10 , wherein the antigen presenting cell is a dendritic cell or a macrophage.

12. The method of claim 5 , wherein the expansion is in the presence of an anti-CD28 antibody and IL-12.

13. The method of claim 1 , wherein the population of activated T cells comprises CD8-positive cells.

14. The method of claim 9 , wherein the contacting is in vitro.

15. The method of claim 1 , wherein the cancer is NSCLC.

16. The method of claim 1 , wherein the cancer is BRCA.

17. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells that kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 6, wherein said cancer is selected from AML, BRCA, CCC, CRC, GBM, GC, HCC, HNSCC, MEL, NHL, NSCLC, OC, OSCAR, RCC, SCLC, UBC, and UEC.

18. The method of claim 17 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.

19. The method of claim 17 , wherein the cancer is NSCLC.

20. The method of claim 17 , wherein the cancer is BRCA.

21. The method of claim 1 , wherein the cancer is AML.

22. The method of claim 1 , wherein the cancer is CCC.

23. The method of claim 1 , wherein the cancer is CRC.

24. The method of claim 1 , wherein the cancer is GBM.

25. The method of claim 1 , wherein the cancer is GC.

26. The method of claim 1 , wherein the cancer is HCC.

27. The method of claim 1 , wherein the cancer is HNSCC.

28. The method of claim 1 , wherein the cancer is MEL.

29. The method of claim 1 , wherein the cancer is NHL.

30. The method of claim 1 , wherein the cancer is OC.

31. The method of claim 1 , wherein the cancer is OSCAR.

32. The method of claim 1 , wherein the cancer is RCC.

33. The method of claim 1 , wherein the cancer is SCLC.

34. The method of claim 1 , wherein the cancer is UBC.

35. The method of claim 1 , wherein the cancer is UEC.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Schuster Heiko
• Hoffgaard Franziska
• Fritsche Jens
• Schoor Oliver
• Weinschenk Toni
• Kowalewski Daniel Johannes
• Tsou Chih-Chiang

Classifications

• A61K40/42

  Cancer antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K35/17 Primary

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title

• A61K39/001118

  Receptors for colony stimulating factors [CSF] · CPC title

• A61K39/001114

  CD74, Ii, MHC class II invariant chain or MHC class II gamma chain · CPC title